Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Dextrose
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Aphaia's Lead Drug Shows Positive Phase 2 Results for Prediabetes
Details : Aphaia's primary drug candidate is APHD-012 (dextrose), a proprietary oral glucose formulation, currently in mid-stage trial for treating patients with type-2 prediabeteic condition.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 20, 2024
Lead Product(s) : Dextrose
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dextrose
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Aphaia Pharma Completes Enrollment in Arm 2 of Phase 2 Trial in Individuals with Obesity
Details : Aphaia's primary drug candidate is APHD-012 (dextrose), a proprietary oral glucose formulation, currently undergoing mid-stage clinical trials for treating patients with obesity.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 13, 2024
Lead Product(s) : Dextrose
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dextrose
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Aphaia Provides Enrollment and Protocol Update for Phase 2 Trial in Obesity Patients
Details : Aphaia's primary drug candidate is APHD-012 (dextrose), a proprietary oral glucose formulation, currently undergoing mid-stage clinical trials for treating patients with obesity.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 25, 2024
Lead Product(s) : Dextrose
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Glucose
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : APH-012 (dextrose) is a glucose formulation, has been shown to safely restore endogenous hormone release in individuals with obesity. It is being evaluated for chronic weight management in patients with obesity and to improve glucose tolerance in patient...
Product Name : Undisclosed
Product Type : Dietary Supplement
Upfront Cash : Inapplicable
April 25, 2023
Lead Product(s) : Glucose
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : APHD-012
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 07, 2023
Lead Product(s) : APHD-012
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Glucose
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase I
Sponsor : NovaClin Medical Research Center S.R.L | ACC GmbH Analytical Clinical Concepts | SC Bioclinica SA | Galephar Pharmaceutical Research (PR), Inc.
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Dietary Supplement
Upfront Cash : Inapplicable
February 21, 2023
Lead Product(s) : Glucose
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase I
Sponsor : NovaClin Medical Research Center S.R.L | ACC GmbH Analytical Clinical Concepts | SC Bioclinica SA | Galephar Pharmaceutical Research (PR), Inc.
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Glucose
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I
Sponsor : ACC GmbH Analytical Clinical Concepts, Germany | Nova-Clin Medical Research Center S.R.L., Romania | Bioclinica | Galephar Pharmaceutical Research (PR), Inc.
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Dietary Supplement
Upfront Cash : Inapplicable
February 06, 2023
Lead Product(s) : Glucose
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Sponsor : ACC GmbH Analytical Clinical Concepts, Germany | Nova-Clin Medical Research Center S.R.L., Romania | Bioclinica | Galephar Pharmaceutical Research (PR), Inc.
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Glucose
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : APH-012 is a glucose formulation designed to be released at discrete parts of the small intestine to restore endogenous nutrient-sensing signaling pathways and stimulate the release of the broad spectrum of enteric hormones that control multiple homeosta...
Product Name : Undisclosed
Product Type : Dietary Supplement
Upfront Cash : Inapplicable
October 27, 2022
Lead Product(s) : Glucose
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : APHD-012
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of Distal Jejunal-release Dextrose in Obese Participants
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 23, 2022
Lead Product(s) : APHD-012
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable